extract: 2025-12-01-who-glp1-guidelines-behavioral-therapy-combination

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -77,6 +77,12 @@ WHO issued conditional recommendations (not full endorsements) for GLP-1s in obe
 
 Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF the typical semaglutide dose when paired with digital behavioral support, matching clinical trial results at 50% drug cost. If this half-dose protocol proves generalizable, it could fundamentally alter the inflationary cost trajectory by reducing per-patient drug spending while maintaining efficacy.
 
+
+### Additional Evidence (challenge)
+*Source: [[2025-12-01-who-glp1-guidelines-behavioral-therapy-combination]] | Added: 2026-03-16*
+
+WHO's conditional rather than unconditional recommendation reflects genuine uncertainty about long-term outcomes and cost-effectiveness, with conditionality based on 'limited long-term efficacy/safety data, current high costs, inadequate health-system preparedness, equity implications.' The guideline's announcement of a 2026 prioritization framework for targeting GLP-1 treatment suggests the field is moving toward selective rather than universal use, which would fundamentally alter the cost trajectory assumptions underlying the 'inflationary through 2035' projection.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -65,6 +65,12 @@ The discontinuation problem is worse than just lost metabolic benefits - it crea
 
 Digital behavioral support may partially solve the persistence problem: UK study showed 11.53% weight loss with engagement vs 8% without at 5 months, suggesting the adherence paradox has a behavioral solution component. However, high withdrawal rates in non-engaged groups suggest this requires active participation, not passive app access.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-12-01-who-glp1-guidelines-behavioral-therapy-combination]] | Added: 2026-03-16*
+
+WHO's conditional recommendation requiring behavioral therapy combination suggests the 15% persistence problem may be addressable through standard-of-care adherence support rather than being an inherent limitation of the medication class. The global guideline's emphasis on 'intensive behavioral therapy to maximize and sustain benefits' positions adherence interventions as essential infrastructure, not optional enhancement.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.json

@@ -0,0 +1,26 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination-establishing-global-standard.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 3,
+    "rejected": 1,
+    "fixes_applied": [
+      "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination-establishing-global-standard.md:set_created:2026-03-16",
+      "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination-establishing-global-standard.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d",
+      "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination-establishing-global-standard.md:stripped_wiki_link:GLP-1 receptor agonists are the largest therapeutic category"
+    ],
+    "rejections": [
+      "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination-establishing-global-standard.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.md

@@ -7,9 +7,13 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: guideline
-status: unprocessed
+status: enrichment
 priority: high
 tags: [who, glp-1, obesity, guidelines, behavioral-therapy, global-health, equity, access, semaglutide, tirzepatide, liraglutide]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -62,3 +66,12 @@ This is worth a separate archive from the basic WHO announcement because the beh
 PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate)
 WHY ARCHIVED: WHO formal guideline establishing behavioral therapy + GLP-1 as global standard of care — this changes the economic model analysis since behavioral support is now the baseline, not an add-on
 EXTRACTION HINT: The conditional recommendation structure and the behavioral therapy requirement are the extractable elements. The basic fact of WHO approving GLP-1s is in the existing archive; this archive is specifically about the standard-of-care implications.
+
+
+## Key Facts
+- WHO issued first-ever global guidelines on GLP-1 medicines for obesity treatment on December 1, 2025
+- Guidelines cover three agents: liraglutide, semaglutide, tirzepatide
+- Recommendations are conditional rather than unconditional
+- Conditionality based on: limited long-term efficacy/safety data, current high costs, inadequate health-system preparedness, equity implications
+- Guidelines published simultaneously in JAMA
+- WHO will develop evidence-based prioritization framework in 2026 to identify which adults with obesity should be prioritized for GLP-1 treatment